



# UNITED STATES PATENT AND TRADEMARK OFFICE

*[Signature]*  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,550	09/01/2006	Hce-Sook Song	13987-00021-US	3089
23416	7590	10/10/2007		
CONNOLLY BOVE LODGE & HUTZ, LLP			EXAMINER	
P O BOX 2207			WORLEY, CATHY KINGDON	
WILMINGTON, DE 19899				
			ART UNIT	PAPER NUMBER
			1638	
			MAIL DATE	DELIVERY MODE
			10/10/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

**Application No.**

10/591,550

**Applicant(s)**

SONG ET AL.

**Examiner**

Cathy K. Worley

**Art Unit**

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-21 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_.
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_.
- ☐ Notice of Informal Patent Application
- ☐ Other: \_\_\_\_.

## DETAILED ACTION

### *Election/Restrictions*

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1 (in part), 2, 3, and 7-15, drawn to a transgenic expression construct comprising the promoter of the *Pisum sativum* ptxA gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:1; and to a transgenic organism comprising said construct.

Group II, claim(s) 1 (in part), 4, 5, and 7-15, drawn to a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a

Art Unit: 1638

promoter defined by its relationship to SEQ ID NO:2; and to a transgenic organism comprising said construct.

Group III, claim(s) 1 (in part), 4, 6 (in part), and 7-15, drawn to a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:7; and to a transgenic organism comprising said construct.

Group IV, claim(s) 1 (in part), 4, 6 (in part), and 7-15, drawn to a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:8; and to a transgenic organism comprising said construct.

Group V, claim(s) 1 (in part), 4, 6 (in part), and 7-15, drawn to a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:9; and to a transgenic organism comprising said construct.

Art Unit: 1638

Group VI, claim(s) 16 (in part) and 17-19, drawn to a method for transgenic expression of a nucleic acid sequence of interest utilizing the promoter of the *Pisum sativum* ptxA gene, or a functional equivalent fragment or a function equivalent homolog thereof.

Group VII, claim(s) 16 (in part) and 17-19, drawn to a method for transgenic expression of a nucleic acid sequence of interest utilizing the promoter of the *Glycine max* extensin (SbHRGP3) gene, or a functional equivalent fragment or a function equivalent homolog thereof.

Group VIII, claim(s) 20 (in part), drawn to the use of a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Pisum sativum* ptxA gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:1.

Group IX, claim(s) 20 (in part), drawn to the use of a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:2.

Art Unit: 1638

Group X, claim(s) 20 (in part), drawn to the use of a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:7.

Group XI, claim(s) 20 (in part), drawn to the use of a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:8.

Group XII, claim(s) 20 (in part), drawn to the use of a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:9.

Group XIII, claim(s) 21 (in part), drawn to a method for production of a foodstuff, animal feed, seed, pharmaceutical, or fine chemical employing a transgenic organism comprising a transgenic expression construct comprising the promoter of

Art Unit: 1638

the *Pisum sativum* ptxA gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:1.

Group XIV, claim(s) 21 (in part), drawn to a method for production of a foodstuff, animal feed, seed, pharmaceutical, or fine chemical employing a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:2.

Group XV, claim(s) 21 (in part), drawn to a method for production of a foodstuff, animal feed, seed, pharmaceutical, or fine chemical employing a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:7.

Group XVI, claim(s) 21 (in part), drawn to a method for production of a foodstuff, animal feed, seed, pharmaceutical, or fine chemical employing a transgenic organism comprising a transgenic expression construct comprising the promoter of

Art Unit: 1638

the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:8.

Group XVII, claim(s) 21 (in part), drawn to a method for production of a foodstuff, animal feed, seed, pharmaceutical, or fine chemical employing a transgenic organism comprising a transgenic expression construct comprising the promoter of the *Glycine max* extensin (SbHRGP3) gene, or functional equivalent fragments or functional equivalent homologs thereof or a promoter defined by its relationship to SEQ ID NO:9.

2. The inventions listed as Groups I-XVII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking groups I-XVII is a construct comprising either the ptxA promoter or the SbHRGP3 promoter. Ahn et al teach a construct comprising the SbHRGP3 promoter driving expression of GUS in transgenic plants (see entire article). Therefore, the technical feature linking the inventions of groups I-XVII does not constitute a special technical feature as defined by PCT Rule 13.2 as it does not define a contribution over the prior art.



Accordingly, Groups I-XVII are not so linked by the same or a corresponding spécial technical feature as to form a single general inventive concept.

3. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require

Art Unit: 1638

the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of an invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cathy K. Worley whose telephone number is (571) 272-8784. The examiner has a variable schedule but can normally be reached on M-F 10:00 - 4:00, with additional variable hours before 10:00 and after 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on (571) 272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Cathy K. Worley  
Patent Examiner  
Art Unit 1638

CKW